According to Stratistics MRC, the Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market is accounted for $148.50 billion in 2019 and is expected to reach $298.07 billion by 2027 growing at a CAGR of 9.1% during the forecast period. Some of the key factors propelling the market growth include growing demand for generic medicines and biologics, growing need for state-of-the-art processes and production technologies, advent of contract development & manufacturing organization (CDMO) model, and growing investment in R&D. However, stringent government regulations are likely to hamper the market.

The contract development and manufacturing organization (CDMO) industry had begun decades ago as a niche business by offering specialty services and manufacturing capacities to pharmaceutical companies. CDMOs also play a critical role in offering additional capacities and mitigate the risk of supply shortages by providing additional manufacturing and development sites and backup facilities. Issues regarding documentation and quality of drug manufacturing process during regulatory reviews can lead to delay in marketing authorization. Therefore for pharmaceutical companies, a prompt quality standard with proven reliability is a definitive key for outsourcing to CDMOs.

By service type, pharmaceutical manufacturing services segment is projected to grow at the lucrative rate during the forecast period, due to the growing need to reduce manufacturing cost, the requirement for high-quality bulk manufacturing, growing demand for generic drugs, high cost of operations, and lack of in-house manufacturing capacity.

On the basis of geography, Asia-Pacific is expected to witness the significant market growth during the forecast period, owing to the low cost offered by the region, as compared to the United States and other developed economies. Additionally, growing incidences of chronic and lifestyle diseases, such as diabetes and heart disease, coupled with ease of patient recruitment and availability of expertise for clinical trials, are few driving factors boosting growth in the region. With the increasing privatization of clinical trials, there has been an increase in the outsourcing of research processes in developing regions like China and India.

Some of the key players in Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market include Famar SA, Boehringer Ingelheim Group, Catalent Inc., Pfizer CentreSource, CMIC Holdings Co. Ltd, Aenova Holding GmbH, Baxter Biopharma Solutions, Syneos Health Inc., Lonza Group , Patheon Inc., Novotech Pty Ltd, Covance Inc., Recipharm AB , SGS SA (SGS Life Sciences), Jubilant Life Sciences Ltd, Samsung Bioepis Co. Ltd, IQVIA Holdings Inc., Quanticate Ltd, PAREXEL International Corporation, and WuXi AppTec Inc.

Research Phases Covered:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Pre-clinical



Service Types Covered:

  • Pharmaceutical Manufacturing Services
  • Biologics Manufacturing Services
  • Drug Development Services



End Users Covered:

  • Small & Mid-size Pharma
  • Big Pharma
  • Generic Pharmaceutical Companies



Regions Covered:

  • North America
  • ·US
  • ·Canada
  • ·Mexico
  • Europe
  • ·Germany
  • ·France
  • ·Italy
  • ·UK
  • ·Spain
  • ·Rest of Europe
  • Asia Pacific
  • ·Japan
  • ·China
  • ·India
  • ·Australia
  • ·New Zealand
  • ·Rest of Asia Pacific
  • South America
  • ·Argentina
  • ·Brazil
  • ·Chile
  • ·Rest of South America
  • Middle East & Africa
  • ·Saudi Arabia
  • ·UAE
  • ·Qatar
  • ·South Africa
  • ·Rest of Middle East & Africa



What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2018, 2019, 2020, 2024 and 2027
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements



Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
  • ·Comprehensive profiling of additional market players (up to 3)
  • ·SWOT Analysis of key players (up to 3)
  • Regional Segmentation
  • ·Market estimations, Forecasts and CAGR of any prominent country as per the client’s interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
  • ·Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances